Basic Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Mar 28, 2015; 21(12): 3537-3546
Published online Mar 28, 2015. doi: 10.3748/wjg.v21.i12.3537
Figure 1
Figure 1 Pathologic changes in the pancreatic and intestinal tissues of the experimental model groups. Pancreatic tissue in A: Control; B: Severe acute pancreatitis (SAP); C: SAP treated with Qingyi decoction (QYT); D: SAP treated with dexamethasone (DEX); and E: SAP treated with verapamil (VER) rats. Intestinal tissue in F: Control; G: SAP; H: QYT-treated); I: DEX-treated; and J: VER-treated rats (hematoxylin and eosin, 100 ×).
Figure 2
Figure 2 Intestinal epithelial cell apoptosis of the experimental model groups. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay in A: Control; B: Severe acute pancreatitis (SAP); C: SAP treated with Qingyi decoction; D: SAP treated with dexamethasone; E: SAP treated with verapamil rats (200 ×).
Figure 3
Figure 3 Electrophoresis micrographs of secreted phospholipase A2 and β-actin mRNA quantitative PCR products. Electrophoresis micrograph of A: sPLA2 mRNA (283 bp); and B: β-actin (as internal control; 531 bp); C: Gray value ratio of sPLA2 to β-actin mRNA expression. aP < 0.05 vs SAP; bP < 0.01 vs CON. CON: Control; DEX: Dexamethasone; M1: 1000 bp-marker; M2: 2000 bp-marker; QYT: Qingyi decoction; SAP: Severe acute pancreatitis; VER: Verapamil.
Figure 4
Figure 4 Secreted phospholipase A2 protein expression in intestinal tissue. A: Western blotting for intestinal tissue sPLA2 protein expression (β-actin was used as the loading control); B: Gray value ratio of sPLA2 to β-actin protein expression. aP < 0.05 vs SAP; bP < 0.01 vs CON. CON: Control; DEX: Dexamethasone; QYT: Qingyi decoction; SAP: Severe acute pancreatitis; VER: Verapamil.